Barclays Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $203.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective reduced by Barclays from $226.00 to $203.00 in a research note issued to investors on Thursday morning, Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Mizuho lifted their price objective on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a buy rating in a report on Friday, May 17th. Bank of America boosted their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a buy rating in a report on Friday, June 21st. BMO Capital Markets boosted their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a report on Monday, June 24th. Oppenheimer raised Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 price target for the company in a report on Tuesday, May 14th. Finally, Piper Sandler cut their price target on Sarepta Therapeutics from $205.00 to $200.00 and set an overweight rating for the company in a report on Thursday. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $186.22.

Sarepta Therapeutics Stock Down 8.1 %

Sarepta Therapeutics stock opened at $125.34 on Thursday. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $173.25. The firm has a market cap of $11.85 billion, a price-to-earnings ratio of 1,139.45 and a beta of 0.89. The stock has a fifty day simple moving average of $140.91 and a two-hundred day simple moving average of $131.59.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. Sarepta Therapeutics’s revenue was up 38.9% compared to the same quarter last year. Equities analysts predict that Sarepta Therapeutics will post 3.76 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the sale, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. International Assets Investment Management LLC raised its holdings in shares of Sarepta Therapeutics by 9,382.5% in the fourth quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company’s stock worth $1,097,000 after buying an additional 11,259 shares during the period. Sapient Capital LLC bought a new stake in Sarepta Therapeutics during the 4th quarter valued at $978,000. WCM Investment Management LLC bought a new stake in Sarepta Therapeutics during the 4th quarter valued at $600,000. Vontobel Holding Ltd. boosted its position in Sarepta Therapeutics by 12.8% during the 4th quarter. Vontobel Holding Ltd. now owns 25,278 shares of the biotechnology company’s stock valued at $2,438,000 after acquiring an additional 2,863 shares in the last quarter. Finally, abrdn plc bought a new stake in Sarepta Therapeutics during the 4th quarter valued at $14,159,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.